

Datasheet: HCA339

BATCH NUMBER 167508

Description:	HUMAN ANTI ECULIZUMAB (DRUG/TARGET COMPLEX)
Specificity:	ECULIZUMAB DRUG/TARGET COMPLEX
Other names:	Soliris
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD32334
Isotype:	HuCAL Fab monovalent
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	A monovalent human recombinant Fab (lambda light chain) selected from the HuCAL phage display library, expressed in <i>E. coli</i> . The antibody is tagged with a DYKDDDDK tag and a His6-tag (HHHHHH). This antibody is supplied as a liquid.
Preparation	Metal chelate affinity chromatography
Source	<i>E.coli</i>
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)
Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml

Immunogen	Eculizumab/C5 complex
Specificity	<p>Human Anti-Eculizumab (Drug/Target Complex) Antibody, clone AbD32334 specifically recognizes the antibody drug eculizumab when in complex with its target, the human complement factor 5 (C5). It does not recognize free eculizumab or unbound C5. It can be used to measure levels of eculizumab and its biosimilars in patient samples.</p> <p>Clone AbD32334 is a complex specific, non-inhibitory Fab monovalent antibody that can be used as a capture antibody for the development of a pharmacokinetic (PK) assay to measure levels of eculizumab/C5 complex in patient serum, together with the Human Anti-C5 Antibody, clone AbD36700 (TZA034) as the detection antibody.</p> <p>Eculizumab (Soliris) is a humanized IgG2/4 kappa antibody. The heavy chains are comprised of human IgG2 sequences in CH1, the hinge and the adjacent portion CH2, and human IgG4 sequences in the remaining part of CH2 and CH3. The drug is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired life-threatening disease of the blood characterized by destruction of red blood cells by the complement system. It also has approval as an orphan drug for treatment of atypical hemolytic uremic syndrome (aHUS). Eculizumab specifically binds to the terminal complement component 5 (C5) and inhibits the cleavage of C5 to C5a and C5b by the C5 convertase, which prevents the generation of the terminal complement complex C5b-9. Both C5a and C5b-9 cause the terminal complement-mediated events that are characteristic of PNH and aHUS. A 1:1 molar ratio of eculizumab to C5 is sufficient for C5 inhibition.</p> <p>View a summary of all anti-eculizumab antibodies</p>
Affinity	The intrinsic affinity of the monovalent form of Human anti Eculizumab (drug/target complex) antibody, clone AbD32334 is $K_D = 57$ nM as measured by real time, label free molecular interaction analysis on immobilized eculizumab in complex with human complement C5.
ELISA	Human anti Eculizumab (drug/target complex) antibody, clone AbD32334 may be used in a PK ELISA as capture antibody for the complex of eculizumab (MCA6145) and human complement C5 in solution together with the Human anti-Human C5 antibody TZA034 as the detection reagent.
Storage	<p>This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.</p> <p>Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.</p>
Guarantee	12 months from date of despatch
Acknowledgements	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.

His-tag is a trademark of EMD Biosciences.
Soliris is a trademark of Alexion Pharmaceuticals, Inc.

Health And Safety Information	Material Safety Datasheet documentation #10040 available at: https://www.bio-rad-antibodies.com/SDS/HCA339 10040
Licensed Use	For <i>in vitro</i> research purposes and for commercial applications for the provision of <i>in vitro</i> testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual .

Related Products

Recommended Useful Reagents

[HUMAN ANTI ECULIZUMAB \(HCA313\)](#)
[HISPEC ASSAY DILUENT \(BUF049A\)](#)
[HUMAN ANTI HUMAN COMPLEMENT C5 \(TZA034\)](#)
[HUMAN ANTI HUMAN COMPLEMENT C5:HRP \(TZA034P\)](#)
[HUMAN ANTI ECULIZUMAB:HRP \(HCA313P\)](#)
[HUMAN ANTI ECULIZUMAB \(HCA315\)](#)
[HUMAN ANTI ECULIZUMAB \(HCA314\)](#)
[HUMAN ANTI ECULIZUMAB \(HCA312\)](#)
[HUMAN ANTI C5 \(ECULIZUMAB BIOSIMILAR\) \(MCA6145\)](#)

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets
'M429269:240408'

Printed on 26 Jun 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)